Health
Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19 – News-Medical.Net
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
The treatment was more effective when administered earlier in the disease course and reduced mortality rates and the need for intubation. Published in the International Journal of Infectious Diseases, the results show Interleukin-6 inhibitors…
-
General23 hours agoNewcastle Jets defeat semi-professional Heidelberg United 3-1 to lift first Australia Cup
-
Noosa News9 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
Noosa News18 hours agoWhat time does the NRL grand final kick off? When is the NRLW grand final?
-
Noosa News15 hours agoMedia adviser launches $4m malicious prosecution claim over kidnap case